Toward The Global Big Pharma League: Yuhan’s Ambitions After Leclaza

Looking To Transcend Korean Pharma's Limits

 
• By Jung Won Shin
  
Generate a summary of this article
Listen to this article
Beta

With Leclaza as a foothold, the next couple of years will be crucial for Yuhan’s ambition to become a top 50 global pharma firm. R&D president Yeul Hong Kim shares how he intends to shape the leading Korean company's efforts to compete with its global rivals.

Yeul Hong Kim, R&D President, Yuhan
Yuhan Looks To Create Virtuous R&D Cycle For Future Growth • Source: Yuhan Corp.

With the launch of novel lung cancer drug Leclaza (lazertinib) in South Korea and other international approvals in sight, Yuhan Corporation is at the starting point of potentially evolving into a competitive global enterprise.

Key Takeaways

  • Yuhan is taking a "select and focus" R&D approach in line with rapidly changing global new drug trends. As part of this strategy, it is focusing on cancer, metabolic disease/obesity and immunology.

To achieve its vision of becoming a top 50 global pharma firm in sales terms by 2026, when it will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

Emerging Modalities Stand Out In Recovering Korean Deal Market

 
• By Jung Won Shin

While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.

Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?

 
• By Jung Won Shin

As investor sentiment around Korean biopharma IPOs and financings remained tepid in the second quarter, companies turned to other ways of raising money, including rights offerings. But there are signs of recovery and upcoming catalysts, while on the M&A front Boryung divested a vaccine subsidiary to a private equity consortium. 

Korea Q2 Roundup: Hanmi Dispute Simmers, Emerging Obesity Focus

 
• By Jung Won Shin

As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.

S.Biomedics’ Parkinson's Cell Therapy Shows Early Clinical Promise

 
• By Jung Won Shin

A novel stem cell therapy for Parkinson’s disease developed by a Korean firm has shown what Citeline analysts describe as "very promising" early clinical results at a low dose after one year.

More from Focus On Asia

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS

 
• By Mandy Jackson

Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.